m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer
Company profile
Ticker
ATHA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
M3 Biotechnology, Inc.
SEC CIK
ATHA stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
28 Mar 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
22 Feb 24
8-K
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
8 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
10 Aug 23
8-K
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
22 May 23
Transcripts
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 110.97 mm | 110.97 mm | 110.97 mm | 110.97 mm | 110.97 mm | 110.97 mm |
Cash burn (monthly) | 1.10 mm | (no burn) | 11.68 mm | 10.78 mm | 7.99 mm | 7.51 mm |
Cash used (since last report) | 6.53 mm | n/a | 69.50 mm | 64.15 mm | 47.57 mm | 44.69 mm |
Cash remaining | 104.43 mm | n/a | 41.47 mm | 46.82 mm | 63.40 mm | 66.28 mm |
Runway (months of cash) | 95.1 | n/a | 3.6 | 4.3 | 7.9 | 8.8 |
Institutional ownership, Q3 2023
58.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 70 |
Opened positions | 7 |
Closed positions | 14 |
Increased positions | 11 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 42.01 bn |
Total shares | 22.40 mm |
Total puts | 9.80 k |
Total calls | 319.50 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 4.80 mm | $9.69 bn |
Baker Bros. Advisors | 3.15 mm | $6.37 bn |
BML Capital Management | 1.70 mm | $3.44 bn |
Vanguard | 1.70 mm | $3.43 bn |
Simplify Asset Management | 1.49 mm | $3.02 bn |
Venrock Healthcare Capital Partners II | 1.00 mm | $0.00 |
Point72 Asset Management | 907.56 k | $1.83 bn |
Millennium Management | 742.34 k | $1.50 bn |
BLK Blackrock | 662.49 k | $1.34 bn |
Dimensional Fund Advisors | 534.45 k | $1.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | Mark James Litton | Stock Option Common Stock | Grant | Acquire A | No | No | 3.66 | 650,000 | 2.38 mm | 650,000 |
14 Feb 24 | Rachel Lenington | Stock Option Common Stock | Grant | Acquire A | No | No | 3.26 | 300,000 | 978.00 k | 300,000 |
14 Feb 24 | Andrew Gengos | Stock Option Common Stock | Grant | Acquire A | No | No | 3.26 | 280,000 | 912.80 k | 280,000 |
14 Feb 24 | Kevin Church | Stock Option Common Stock | Grant | Acquire A | No | No | 3.26 | 220,000 | 717.20 k | 220,000 |
14 Feb 24 | Mark Worthington | Stock Option Common Stock | Grant | Acquire A | No | No | 3.26 | 220,000 | 717.20 k | 220,000 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Mar 24
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference
8 Mar 24
Athira Pharma Announces Publication In Frontiers In Neuroscience Highlighting Therapeutic Potential Of ATH-1105 In Amyotrophic Lateral Sclerosis
8 Feb 24
Athira Pharma Provides 2024 Clinical Pipeline Outlook; Topline Data From Phase 2/3 LIFT-AD Trial Of Fosgonimeton For Mild-to-moderate Alzheimer's Disease Expected In 2H Of 2024;
8 Jan 24
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
2 Jan 24
Press releases
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference
8 Mar 24
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
8 Feb 24
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease
3 Jan 24